Sat 12 February 2022:
Pfizer’s COVID-19 medication Paxlovid has received “conditional” approval in China to treat adults with mild to moderate sickness and a high risk of developing severe disease.
The medicine has been approved in around 40 nations so far, with the European Union allowing member states to use it as an emergency measure against the rapidly spreading Omicron coronavirus type before formal approval.
“This is an important milestone in our fight against COVID-19,” a Pfizer spokesperson stated in a statement, without elaborating on the procurement process.
China’s National Medical Products Administration on Saturday said further research on the drug needed to be undertaken and submitted to the regulator.
Beijing has not yet approved any foreign-made coronavirus vaccines.
Earlier this week, Pfizer, whose vaccine developed with Germany’s BioNTech was the first approved in the United States, forecast more than $50bn in 2022 sales for its coronavirus jab and therapeutic treatment.
The company expects to make 120 million treatment courses of Paxlovid, with executives describing ongoing contract talks with about 100 governments.
SOURCE: INDEPENDENT PRESS AND NEWS AGENCIES
_____________________________________________________________________________________________________________
FOLLOW INDEPENDENT PRESS:
TWITTER (CLICK HERE)
https://twitter.com/IpIndependent
FACEBOOK (CLICK HERE)
https://web.facebook.com/ipindependent
Think your friends would be interested? Share this story!
